The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to At Least 3 Months
Maximum Observed Serum Concentration (Cmax) of ABBV-8736
Timeframe: Up to At Least 3 Months
Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736
Timeframe: Up to At Least 3 Months
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736
Timeframe: Up to At Least 3 Months
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736
Timeframe: Up to At Least 3 Months
Terminal Phase Elimination Rate Constant (β) of ABBV-8736
Timeframe: Up to At Least 3 Months
Terminal Elimination Half-Life (t1/2) of ABBV-8736
Timeframe: Up to At Least 3 Months
Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736
Timeframe: Up to At Least 3 Months